CareDx, Inc. (CDNA) fair value analysis
Nasdaq · Updated 2026-10-19
CDNA price how computed
Forward Fair Value verdict
OvervaluedCDNA is trading at more than a 25% premium to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $64.00
- Sector
- Healthcare
- 12-month range
- $14.28–$69.85
- Market cap
- $3.31B
- From 52-week high
- -8.4%
- Shares outstanding
- 51.7M
- Rank in Healthcare by discount to fair value
- #94 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
CareDx, Inc. is a healthcare company that develops and commercializes diagnostic solutions for transplant patients, focusing on monitoring organ rejection and transplant outcomes. The company operates in the United States and internationally, serving transplant centers and patients worldwide through its molecular testing and monitoring platforms.
CDNA currently ranks #94 of 108 Healthcare stocks by discount to fair value. It has screened as Overvalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $3.31B
- P/E (trailing)
- 70x
- Revenue (TTM)
- $458M
- Net margin
- 24.2%
- EPS (TTM)
- $0.91
- Gross margin
- 73.5%
- Debt / equity
- 0.05
- Revenue growth (3-yr avg)
- 32.1%
- Shares outstanding
- 51.7M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Expanding
- 52-week position
- The top quarter of its range
Technicals how computed
- RSI (14-day)
- 61 · neutral
- 50-day average
- $54.95
- 200-day average
- $31.02
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Earnings how computed
- Next earnings report
- 2026-10-29 (post-market)
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+183.3%)
2026-03 ▲ beat (+161.5%)
2025-12 ▲ beat (+1300.0%)
2025-09 ▲ beat (+100.0%)
2025-06 ▼ miss (-16.7%)
2025-03 ▲ beat (+42.9%)
2024-12 ▲ beat (+22.0%)
2024-09 ▲ beat (+1300.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 5 buy · 2 hold · 0 sell (7 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $61.7
- Target vs last price
- -3.6%
What our data shows for CDNA
- Our model validated 7 trailing price-to-earnings windows for CDNA, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $14.28–$69.85.
- The 14-day relative strength index sits at a neutral 61.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for CDNA
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent CDNA news
TickrTrends' derived news-sentiment signal for CDNA is currently leaning positive, computed from recent coverage.
- CareDx Inc (CDNA) Shares Surge 4.8% -- What GF Score of 64 Tells Investors (gurufocus.com, 2026-10-20)
TickrTrends take: CareDx shares recently gained 4% in trading activity, yet TickrTrends currently derives an Overvalued verdict for the Healthcare company. A GF Score of 64 suggests moderate quality fundamentals that may not justify the stock's current market price relative to its valuation metrics. Investors focused on valuation should monitor whether the recent price movement narrows the gap between market price and intrinsic value, or whether the Overvalued assessment persists despite positive momentum. - CDNA Maintained by Canaccord Genuity -- Price Target Raised to $80 (gurufocus.com, 2026-10-19)
TickrTrends take: Canaccord Genuity raised its price target for CDNA to $80, reflecting analyst confidence in the company's prospects within the Healthcare sector. However, TickrTrends currently indicates that CDNA trades at an overvalued level relative to its fundamentals, suggesting the analyst's target may not align with current valuation metrics. Investors focused on valuation should monitor whether CDNA's financial performance and growth rates can justify closing the gap between the new price target and the stock's current trading levels. - CareDx Inc (CDNA) Shares Fall 4.0% -- GF Value Says Still Overvalued (gurufocus.com, 2026-10-17)
TickrTrends take: CareDx shares declined 4 percent following a reaffirmation of its overvalued status according to GuruFocus valuation metrics, yet TickrTrends maintains the same overvalued assessment despite the stock movement. For investors focused on valuation in the Healthcare sector, the persistence of an overvalued rating even after a price decline suggests the company's valuation multiples may remain elevated relative to fundamental metrics. Observers tracking CDNA should monitor whether further price adjustments occur or if the gap between market valuation and intrinsic value estimates continues to warrant caution.
More CDNA news
- CareDx Inc (CDNA) Stock Up 3.7% but GF Value Says Overvalued -- GF Score: 64/100 (gurufocus.com, 2026-10-13)
- A Look at CareDx Inc (CDNA) After 4.0% Gain -- GF Value $25.50 vs Price $69.85 (gurufocus.com, 2026-10-06)
- CareDx Inc (CDNA) Stock Up 13.0% but GF Value Says Overvalued -- GF Score: 66/100 (gurufocus.com, 2026-09-25)
What people are saying
Follow the CDNA conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for CDNA showed a notable shift this week as the Relative Strength Index moved from overbought territory into neutral zone. The stock, which operates in the Healthcare sector, remains classified as overvalued according to current valuation metrics. This moderation in the RSI suggests reduced upward momentum compared to the previous week's assessment.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — CDNA's RSI zone moved from neutral to overbought this week, indicating strengthening upward momentum in the stock's recent price action. The company's sector discount rank declined to 112 from 107, meaning it has become less attractively valued relative to other Healthcare sector stocks. With a current valuation verdict of Overvalued, CDNA's technical indicators and relative valuation metrics both suggest limited near-term value at present levels.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is CDNA stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), CDNA is trading at more than a 25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.
What is CDNA's TickrTrends verdict?
CDNA's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.
How does CDNA compare to other Healthcare stocks?
CDNA ranks #94 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is CDNA overbought or oversold?
CDNA's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does CDNA report earnings next?
CDNA's next earnings report is scheduled for 2026-10-29 (post-market), per the published earnings calendar.
Does CDNA usually beat earnings estimates?
Over its last 8 reported quarters CDNA beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about CDNA?
Of 7 analysts covering CDNA, 5 rate it a buy, 2 a hold and 0 a sell - buy-leaning, with a consensus price target of $61.7 (-3.6% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
CDNA vs ALKS · CDNA vs CRL · CDNA vs DCTH · CDNA vs HUM · CDNA vs ILMN